Business
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for
About this update from Boundless Bio, Inc.
[{"type":"image","alt":"Boundless Bio, Inc.","displaySize":"","headline":null,"caption":"Boundless Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":255,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/445cbf87d86da6c7106a163824081ecf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wDQrk2ofC9C.FYdGf39x7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/445cbf87d86da6c7106a163824081ecf","width":255,"height":38},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/wDQrk2ofC9C.FYdGf39x7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/445cbf87d86da6c7106a163824081ecf","width":255,"height":38}},"lazy":false},{"type":"text","content":"Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940","length":74,"tagName":"p"},{"type":"text","content":"$93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1","length":99,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026.","length":365,"tagName":"p"},{"type":"text","content":"“We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “We continue to expand the body of evidence supporting BBI-940’s kinesin degradation mechanism, with our recent AACR poster demonstrating anti-tumor activity and tumor regression across multiple ecDNA+ cancer models. These findings further strengthen our confidence in the therapeutic potential of BBI-940 as we advance the program through a first-in-human clinical trial.”","length":514,"tagName":"p"},{"type":"text","content":"Business Highlights and Upcoming Milestones","length":43,"tagName":"p"},{"type":"text","content":"BBI-940 Novel Kinesin Degrader Clinical Program","length":47,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment is ongoing in KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology-1), a first-in-human clinical trial of BBI-940 i...